$BDPT
BIOADAPTIVES, INC. Stock $bdpt

$bdpt Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000164033423000532 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$3.376K	$3.980K	$17.18K
YoY Change	-38.98%	3.38%	-13.15%
Cost Of Revenue	$1.396K	$2.950K	$10.05K
YoY Change	-61.11%	8.86%	3.92%
Gross Profit	$1.980K	$1.030K	$7.126K
YoY Change	1.9%	-9.65%	-29.48%
Gross Profit Margin	58.65%	25.88%	41.49%
Selling, General & Admin	$20.29K	$27.65K	$366.9K
YoY Change	-85.81%	-79.84%	-28.4%
% of Gross Profit	1024.75%	2684.47%	5148.47%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$670.00	$690.00	$62.15K
YoY Change	-97.98%	-98.35%	-53.55%
% of Gross Profit	33.84%	66.99%	872.16%
Operating Expenses	$20.96K	$28.34K	$429.0K
YoY Change	-88.11%	-84.16%	-33.61%
Operating Profit	-$18.98K	-$27.31K	-$421.9K
YoY Change	-89.11%	-84.63%	-33.67%
Interest Expense	$51.06K	-$980.00	$289.1K
YoY Change	69.65%	-97.32%	6.14%
% of Operating Profit
Other Income/Expense, Net	-$268.2K		-$473.7K
YoY Change	39.06%		-214.45%
Pretax Income	-$287.2K	-$28.28K	-$895.6K
YoY Change	-21.77%	-86.8%	-14.7%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$287.2K	-$28.28K	-$895.6K
YoY Change	-21.78%	-86.8%	-14.7%
Net Earnings / Revenue	-8506.72%	-710.55%	-5214.08%
Basic Earnings Per Share
Diluted Earnings Per Share	$0.00	$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	355.6M shares	160.5M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.980K	$25.45K	$25.45K
YoY Change	-89.31%	-69.39%	-69.39%
Cash & Equivalents	$5.944K	$25.41K
Short-Term Investments	$30.00	$40.00	$40.00
Other Short-Term Assets		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Inventory	$4.743K	$8.877K	$8.880K
Prepaid Expenses		$0.00
Receivables
Other Receivables
Total Short-Term Assets	$10.72K	$34.32K	$34.32K
YoY Change	-82.29%	-61.38%	-61.39%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$2.320K	$2.990K	$2.990K
YoY Change	-91.26%	-94.99%	-94.99%
TOTAL ASSETS
Total Short-Term Assets	$10.72K	$34.32K	$34.32K
Total Long-Term Assets	$2.320K	$2.990K	$2.990K
Total Assets	$13.04K	$37.31K	$37.31K
YoY Change	-85.02%	-74.89%	-74.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.644K	$6.939K	$409.9K
YoY Change	-99.49%	296.51%	65.46%
Accrued Expenses	$1.019K	$1.015K
YoY Change	-98.61%	-90.77%
Deferred Revenue
YoY Change
Short-Term Debt	$357.6K	$392.0K	$392.0K
YoY Change	-16.34%	-10.25%	-10.25%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.644M	$1.489M	$1.489M
YoY Change	10.67%	19.91%	19.91%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.644M	$1.489M	$1.489M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.644M	$1.489M	$1.489M
YoY Change	10.67%	19.91%	19.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$7.839M	-$7.552M
YoY Change	8.17%	13.45%
Common Stock	$38.49K	$25.26K
YoY Change		396.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.631M	-$1.452M	-$1.452M
YoY Change
Total Liabilities & Shareholders Equity	$13.04K	$37.31K	$37.31K
YoY Change	-85.02%	-74.89%	-74.89%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$287.2K	-$28.28K	-$895.6K
YoY Change	-21.78%	-86.8%	-14.7%
Depreciation, Depletion And Amortization	$670.00	$690.00	$62.15K
YoY Change	-97.98%	-98.35%	-53.55%
Cash From Operating Activities	-$19.46K	-$27.50K	-$227.3K
YoY Change	-68.18%	-22.32%	43.24%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$271.6K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	35.00K	$169.7K
YoY Change	-100.0%	-32.69%	-28.38%
NET CHANGE
Cash From Operating Activities	-$19.46K	-27.50K	-$227.3K
Cash From Investing Activities
Cash From Financing Activities	$0.00	35.00K	$169.7K
Net Change In Cash	-$19.46K	7.500K	-$57.53K
YoY Change	-28.31%	-54.82%	-173.43%
FREE CASH FLOW
Cash From Operating Activities	-$19.46K	-$27.50K	-$227.3K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	51000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001575142
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89128
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50819780	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	252554765	shares
CY2021Q4	bdpt	Common Stock Capital Shares Reserved For Future Issuance1 CommonStockCapitalSharesReservedForFutureIssuance1	10000	shares
CY2021	bdpt	Ending Balance EndingBalance	557042	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q4	bdpt	Preferred Stock Par Or Stated Value Per Share1 PreferredStockParOrStatedValuePerShare1	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1250000000	shares
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	000-54949
CY2022	dei	Entity Registrant Name EntityRegistrantName	BioAdaptives, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-2592228
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2620 Regatta Drive
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 102
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Las Vegas
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2022	dei	City Area Code CityAreaCode	702
CY2022	dei	Local Phone Number LocalPhoneNumber	659-8829
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Public Float EntityPublicFloat	324563	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	355632566	shares
CY2022	dei	Auditor Name AuditorName	BF Borgers CPA PC
CY2022	dei	Auditor Firm AuditorFirmId	5041
CY2022	dei	Auditor Location AuditorLocation	Lakewood, CO
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25405	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82936	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	0	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	42	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	190	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	8877	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4750	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	34324	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	88876	usd
CY2022Q4	us-gaap	Indefinite Lived License Agreements IndefiniteLivedLicenseAgreements	2990	usd
CY2021Q4	us-gaap	Indefinite Lived License Agreements IndefiniteLivedLicenseAgreements	59709	usd
CY2022Q4	us-gaap	Assets Assets	37314	usd
CY2021Q4	us-gaap	Assets Assets	148585	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	409920	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	247750	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	686856	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	557042	usd
CY2022Q4	bdpt	Convertible Notes Net Of Discount ConvertibleNotesNetOfDiscount	7647	usd
CY2021Q4	bdpt	Convertible Notes Net Of Discount ConvertibleNotesNetOfDiscount	13333	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	381793	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	403117	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	10246	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	33715	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1488815	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1241624	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1488815	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1241624	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	252554765	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50819780	shares
CY2022Q4	bdpt	Common Stock Capital Shares Reserved For Future Issuance1 CommonStockCapitalSharesReservedForFutureIssuance1	10000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	25255	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	5082	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6074763	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5557828	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7551679	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-6656109	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1451501	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1093039	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37314	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	148585	usd
CY2022	us-gaap	Revenues Revenues	17176	usd
CY2021	us-gaap	Revenues Revenues	19776	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	10050	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	9671	usd
CY2022	us-gaap	Gross Profit GrossProfit	7126	usd
CY2021	us-gaap	Gross Profit GrossProfit	10105	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	254119	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	268268	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	112759	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	80227	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	163900	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	62148	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	1803	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	133791	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	429026	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	646186	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-148	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-254	usd
CY2022	us-gaap	Interest Expense InterestExpense	289121	usd
CY2021	us-gaap	Interest Expense InterestExpense	272394	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-184401	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-90219	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-473670	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-413867	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-895570	usd
CY2021	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-1049948	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-895570	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1049948	usd
CY2022	bdpt	Basic And Diluted Earning Per Share BasicAndDilutedEarningPerShare	-0.01
CY2021	bdpt	Basic And Diluted Earning Per Share BasicAndDilutedEarningPerShare	-0.03
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	106011449	shares
CY2021	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	33742920	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-1378785	usd
CY2021	bdpt	Series A Preferred Stock Issued For Settlement Of Debt Related Party Amount SeriesAPreferredStockIssuedForSettlementOfDebtRelatedPartyAmount	75000	usd
CY2021	bdpt	Series A Preferred Stock Issued For License Fee Amount SeriesAPreferredStockIssuedForLicenseFeeAmount	193500	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	856627	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	163900	usd
CY2021	bdpt	Cancellation Of Common Stock Officers Amount CancellationOfCommonStockOfficersAmount	0	usd
CY2021	bdpt	Debts Forgiveness Related Party DebtsForgivenessRelatedParty	46667	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1049948	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-1093039	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	521679	usd
CY2022	bdpt	Debts Forgiveness Related Party DebtsForgivenessRelatedParty	10000	usd
CY2022	bdpt	Warrant Issued For Patent S Acquisition WarrantIssuedForPatentSAcquisition	5429	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-895570	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1451501	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-895570	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1049948	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	0	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	163900	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	184401	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	90219	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	62148	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	133791	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	239186	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	216931	usd
CY2022	bdpt	Loss On Settlement Of Debt LossOnSettlementOfDebt	0	usd
CY2021	bdpt	Loss On Settlement Of Debt LossOnSettlementOfDebt	-51000	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-148	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-254	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4127	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-9065	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	183752	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	227137	usd
CY2021	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-227259	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-158651	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1623	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1623	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1623	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	1623	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	25272	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	20000	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	195000	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	257000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	169728	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	237000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-57531	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	78349	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82936	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4587	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25405	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82936	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	4728	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	16424	usd
CY2022	us-gaap	Separate Account Liability Period Increase Decrease SeparateAccountLiabilityPeriodIncreaseDecrease	217000	usd
CY2021	us-gaap	Separate Account Liability Period Increase Decrease SeparateAccountLiabilityPeriodIncreaseDecrease	205000	usd
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	521679	usd
CY2021	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	856627	usd
CY2022	us-gaap	Proceeds From Issuance Of Trust Preferred Securities ProceedsFromIssuanceOfTrustPreferredSecurities	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Trust Preferred Securities ProceedsFromIssuanceOfTrustPreferredSecurities	193500	usd
CY2022	bdpt	Issuance Series A Preferred Stock For Settlement Of Debt Related Party IssuanceSeriesAPreferredStockForSettlementOfDebtRelatedParty	0	usd
CY2021	bdpt	Issuance Series A Preferred Stock For Settlement Of Debt Related Party IssuanceSeriesAPreferredStockForSettlementOfDebtRelatedParty	60	usd
CY2022	bdpt	Debts Forgiveness Related Party DebtsForgivenessRelatedParty	10000	usd
CY2021	bdpt	Debts Forgiveness Related Party DebtsForgivenessRelatedParty	46667	usd
CY2022	bdpt	Warrant Issued For Patents Acquisition WarrantIssuedForPatentsAcquisition	5429	usd
CY2021	bdpt	Warrant Issued For Patents Acquisition WarrantIssuedForPatentsAcquisition	0	usd
CY2022	bdpt	Cancellation Of Common Stock CancellationOfCommonStock	0	usd
CY2021	bdpt	Cancellation Of Common Stock CancellationOfCommonStock	35	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25405	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82936	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1142061477	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	65513358	shares
CY2022	us-gaap	Revenue Recognition Leases RevenueRecognitionLeases	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">identify the contract with a customer;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">identify the performance obligations in the contract;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">determine the transaction price;</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">allocate the transaction price to performance obligations in the contract; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">·</span></p></td><td style="vertical-align:top;">recognize revenue as the performance obligation is satisfied.</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="text-decoration:underline">Cost of revenue</span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Cost of revenue includes the inventory purchased from a related party.</p>
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	42	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	686856	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	190	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	557042	usd
CY2022Q4	bdpt	Retained Earning Accumulated Deficit RetainedEarningAccumulatedDeficit	-7551179	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	42	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	190	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6939	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1750	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	300000	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	166666	usd
CY2022Q4	bdpt	Accrued Interest Current AccruedInterestCurrent	101966	usd
CY2021Q4	bdpt	Accrued Interest Current AccruedInterestCurrent	68341	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1015	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10993	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	409920	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	247750	usd
CY2022Q4	bdpt	Total Convertible Notes Payable TotalConvertibleNotesPayable	389440	usd
CY2021Q4	bdpt	Total Convertible Notes Payable TotalConvertibleNotesPayable	416450	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	7647	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	13333	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	381793	usd
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	403117	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	381793	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	403117	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	usd
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	usd
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	49402	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	53660	usd
CY2022Q4	bdpt	Convertible Notes Accrued Interest ConvertibleNotesAccruedInterest	100919	usd
CY2021Q4	bdpt	Convertible Notes Accrued Interest ConvertibleNotesAccruedInterest	63100	usd
CY2022	bdpt	Amortization Of Debt Discount AmortizationOfDebtDiscount	239186	usd
CY2021	bdpt	Amortization Of Debt Discount AmortizationOfDebtDiscount	216931	usd
CY2022	us-gaap	Debt Instrument Convertible If Converted Value In Excess Of Principal DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal	238510	usd
CY2022	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	11582	usd
CY2022	bdpt	Convertible Shares Of Common Stock ConvertibleSharesOfCommonStock	201734985	shares
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	271587	usd
CY2021	us-gaap	Debt Instrument Convertible If Converted Value In Excess Of Principal DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal	271050	usd
CY2021	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	20281	usd
CY2021	bdpt	Convertible Shares Of Common Stock ConvertibleSharesOfCommonStock	28580228	shares
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	565296	usd
CY2022	bdpt	Value Assigned Of Derivatives Liabilities ValueAssignedOfDerivativesLiabilities	276414	usd
CY2022	bdpt	Debt Discount DebtDiscount	217000	usd
CY2022	bdpt	Derivative Loss On Derivative1 DerivativeLossOnDerivative1	59414	usd
CY2021	bdpt	Value Assigned Of Derivatives Liabilities ValueAssignedOfDerivativesLiabilities	358697	usd
CY2021	bdpt	Debt Discount DebtDiscount	205000	usd
CY2021	bdpt	Derivative Loss On Derivative1 DerivativeLossOnDerivative1	153697	usd
CY2022	bdpt	Expected Dividend Yield ExpectedDividendYield	0	pure
CY2021	bdpt	Expected Dividend Yield ExpectedDividendYield	0	pure
CY2021	bdpt	Beginning Balance BeginningBalance	827119	usd
CY2021	bdpt	Addition Of New Derivatives Recognized As Debt Discounts AdditionOfNewDerivativesRecognizedAsDebtDiscounts	205000	usd
CY2021	bdpt	Addition Of New Derivatives Recognized As Loss On Derivatives AdditionOfNewDerivativesRecognizedAsLossOnDerivatives	153697	usd
CY2021	bdpt	Settled On Issuance Of Common Stock SettledOnIssuanceOfCommonStock	-565296	usd
CY2021	bdpt	Gain Loss On Change In Fair Value Of The Derivative Liabilities GainLossOnChangeInFairValueOfTheDerivativeLiabilities	-63478	usd
CY2022	bdpt	Beginning Balance BeginningBalance	557042	usd
CY2022	bdpt	Addition Of New Derivatives Recognized As Debt Discounts AdditionOfNewDerivativesRecognizedAsDebtDiscounts	217000	usd
CY2022	bdpt	Addition Of New Derivatives Recognized As Loss On Derivatives AdditionOfNewDerivativesRecognizedAsLossOnDerivatives	59414	usd
CY2022	bdpt	Settled On Issuance Of Common Stock SettledOnIssuanceOfCommonStock	-271587	usd
CY2022	bdpt	Gain Loss On Change In Fair Value Of The Derivative Liabilities GainLossOnChangeInFairValueOfTheDerivativeLiabilities	124987	usd
CY2022	bdpt	Ending Balance EndingBalance	686856	usd
CY2022	bdpt	Loss On Derivative Instruments Related Convertible Notes LossOnDerivativeInstrumentsRelatedConvertibleNotes	59414	usd
CY2021	bdpt	Loss On Derivative Instruments Related Convertible Notes LossOnDerivativeInstrumentsRelatedConvertibleNotes	153697	usd
CY2022	bdpt	Gain Loss On Change In Fair Value Of The Derivative Liabilities GainLossOnChangeInFairValueOfTheDerivativeLiabilities	124987	usd
CY2021	bdpt	Gain Loss On Change In Fair Value Of The Derivative Liabilities GainLossOnChangeInFairValueOfTheDerivativeLiabilities	-63478	usd
CY2022	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	184401	usd
CY2021	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	90219	usd
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	bdpt	Preferred Stock Par Or Stated Value Per Share1 PreferredStockParOrStatedValuePerShare1	0.001
CY2022Q4	bdpt	Common Stock Capital Shares Reserved For Future Issuance1 CommonStockCapitalSharesReservedForFutureIssuance1	10000	shares
CY2022	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	201734985	shares
CY2022	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	521679	usd
CY2021	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	28580228	shares
CY2021	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	856627	usd
CY2021	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	1000000	shares
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	163900	usd
CY2021	bdpt	Common Stock Cancelled Shares CommonStockCancelledShares	352390	shares
CY2022Q1	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	0.006
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	5429	usd
CY2022	bdpt	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm	P2Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.35	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0131	pure
CY2021Q4	bdpt	Related Party Debt Settlement RelatedPartyDebtSettlement	75000	usd
CY2021Q4	bdpt	Settlement Amount SettlementAmount	24000	usd
CY2021	bdpt	Loss On Settlement Of Debt LossOnSettlementOfDebt	-51000	usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	25272	usd
CY2021	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	20000	usd
CY2022	us-gaap	Interest Paid InterestPaid	533	usd
CY2021	us-gaap	Interest Paid InterestPaid	1803	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	8444	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	33716	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1047	usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	5241	usd
CY2022	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.04	pure
CY2022	bdpt	Increase Decrease In Accrued Salaries Payable IncreaseDecreaseInAccruedSalariesPayable	133334	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	300000	usd
CY2021	bdpt	Increase Decrease In Accrued Salaries Payable IncreaseDecreaseInAccruedSalariesPayable	213333	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	166666	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	99116	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	155988	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	99116	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	155988	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	525212	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	426096	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	525212	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	426096	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022	us-gaap	Gain Loss On Sale Of Leased Assets Net Operating Leases GainLossOnSaleOfLeasedAssetsNetOperatingLeases	2501000	usd
CY2022	bdpt	Articles Of In Corporation Description ArticlesOfInCorporationDescription	On March 7, 2023, the Company amended its articles of incorporation to increase its authorized common shares from 750,000,000 to 1,250,000,000; this increase will be effective March 27, 2022

Files In Submission

Name	View Source	Status
0001640334-23-000532-index-headers.html	Edgar Link	pending
0001640334-23-000532-index.html	Edgar Link	pending
0001640334-23-000532.txt	Edgar Link	pending
0001640334-23-000532-xbrl.zip	Edgar Link	pending
bdpt-20221231.xsd	Edgar Link	pending
bdpt-20221231_pre.xml	Edgar Link	unprocessable
bdpt-20221231_def.xml	Edgar Link	unprocessable
bdpt-20221231_cal.xml	Edgar Link	unprocessable
bdpt-20221231_lab.xml	Edgar Link	unprocessable
bdpt_10k.htm	Edgar Link	pending
bdpt_10kimg11.jpg	Edgar Link	pending
bdpt_ex31.htm	Edgar Link	pending
bdpt_ex311.htm	Edgar Link	pending
bdpt_ex312.htm	Edgar Link	pending
bdpt_ex31img3.jpg	Edgar Link	pending
bdpt_ex321.htm	Edgar Link	pending
bdpt_ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
bdpt_10k_htm.xml	Edgar Link	completed
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BDPT
BIOADAPTIVES, INC. Stock $bdpt

2023 Q1 Form 10-K Financial Statement

#000164033423000532 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BDPT BIOADAPTIVES, INC. Stock $bdpt

2023 Q1 Form 10-K Financial Statement

#000164033423000532 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BDPT
BIOADAPTIVES, INC. Stock $bdpt